Latest news
Business Update
Innosuisse-Funded Alzheimer’s Clinical Trial with MIAMIND®
The MIAMIND® electrical neurostimulator will be evaluated in a randomized, sham-controlled clinical trial in patients with early-stage Alzheimer’s disease (AD), supported by funding from Innosuisse.
08 April, 2026
Read more
Events & Conferences | Tue 09, 2023
Bottneuro at the Swiss Medtech Expo Symposium
At the Swiss Medtech Expo symposium on Wednesday, September 13, 2023, everything will revolve around application examples from manufacturing.
Business Update | Fri 09, 2023
Miamind® Neurostimulator Achieves Official Certification from DEKRA
Bottneuro has received official confirmation from DEKRA that the Miamind® Neurostimulator has successfully passed all relevant external device tests.
Business Update | Mon 03, 2023
Followup to Bottneuro's collaboration with Samsung!
Today Bottneuro was featured in Samsung Global Newsroom, Samsung Mobile and several newspapers in South Korea.
Business Update | Wed 02, 2023
Partnership Samsung & Bottneuro
Bottneuro has entered into a technology partnership with Samsung to support its innovative approach to treating Alzheimer's disease.
Featured news
Bottneuro Team
Dr Antonella Santuccione Chadha joins the Board of Directors at Bottneuro
02 June, 2025
